- Home
- MIRM vs ESE Comparison
MIRM vs ESE Comparison
Compare MIRM & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | ESE |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.2B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | ESE |
|---|---|---|
| Price | $93.69 | $313.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | $115.33 | ★ $283.33 |
| AVG Volume (30 Days) | ★ 702.8K | 347.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | 74.59 | ★ 193.15 |
| EPS | N/A | ★ 1.11 |
| Revenue | $19,138,000.00 | ★ $37,000,000.00 |
| Revenue This Year | $26.22 | $21.42 |
| Revenue Next Year | $22.04 | $6.99 |
| P/E Ratio | ★ N/A | $282.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.18 | $152.92 |
| 52 Week High | $109.28 | $319.14 |
Technical Indicators
Market Signals| Indicator | MIRM | ESE |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 63.02 |
| Support Level | $85.35 | $198.85 |
| Resistance Level | $98.03 | N/A |
| Average True Range (ATR) | 3.39 | 9.58 |
| MACD | 0.06 | 0.62 |
| Stochastic Oscillator | 20.06 | 85.41 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About ESE ESCO Technologies Inc.
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.